 |
|
|
| |
Failure with All-oral DAA Regimens: Real-world experience from the TRIO Network.
Academic and community treatment of a real-world, heterogeneous population
|
| |
| |
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Nezam Afdhal1, Bruce Bacon2, Douglas Dieterich 3, Steven L. Flamm4, Lauren Guest5, Kris V. Kowdley6,Yoori Lee5, Naoky Tsai7, Zobair Younossi8
1Beth Israel Deaconess Medical Center, 2Saint Louis University School of Medicine, 3Mount Sinai School of Medicine, 4Northwestern University Feinberg School of Medicine, 5Trio Health Analytics, 6 Swedish Liver Center and Transplant Program, Swedish Medical Center, 7 Queens Medical Center, University of Hawaii, 8Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital
from Jules: of note is TRIO finding of lower SVR rates when patients were treated outside the Guidelines, see slides below as to how but it included not using Rbv with Harvoni in cirrhotics, not using Rbv along with Viekira Pak, and appears not using Viekira Pak.Rbv appropriately. Also note the differences in SVR between Harvoni with & without Rbv which may be due to treating outside the Guidelines when Rbv is recommended.
|
| |
|
|
|
|
|
